Bevacizumab Biosimilars Market By Indication (Colorectal Cancer, Lung Cancer, Renal Cell Carcinoma, Others); By Distribution Channel (Hospital Pharmacies, Specialty Clinics, Online & Retail Pharmacies); By End User (Large Hospitals & Cancer Institutes, Community Oncology Clinics, Research & Academic Institutions); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Bevacizumab Biosimilars Market will witness a robust CAGR of around 17.0 %, valued at approximately USD 3.6 billion in 2024, expected to appreciate and reach nearly USD 9.2 billion by 2030 , confirms Strategic Market Research.

 

Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF), widely used in oncology for inhibiting tumor angiogenesis. With the original Avastin losing exclusivity in major regions, biosimilars are stepping in to expand access to life-saving therapies. Between 2024 and 2030, the market’s strategic relevance will grow sharply as healthcare systems increasingly rely on cost-effective biologics to manage the soaring cancer burden.

 

The backdrop is clear. Global cancer incidence is rising, particularly colorectal, lung, and renal cancers where bevacizumab plays a central role. At the same time, biologics remain expensive, straining payer budgets and limiting patient access in low- and middle-income regions. Biosimilars address this gap by offering similar efficacy and safety profiles at significantly lower cost, creating a dual benefit: affordability for patients and savings for healthcare systems.

 

Another important context is regulation. Agencies such as the FDA, EMA, and regulatory bodies in Asia are accelerating biosimilar approvals. Streamlined pathways, supportive interchangeability policies, and incentives for generic competition are strengthening adoption. That said, uptake is not uniform—some markets still face physician hesitancy, complex reimbursement landscapes, and patient trust issues.

 

Technology is also reshaping this space. Advances in biologics manufacturing, improved analytical characterization, and investments in pharmacovigilance are increasing confidence in biosimilars. Several biosimilar developers are building global-scale manufacturing hubs, ensuring consistent supply and positioning themselves as trusted suppliers.

 

The stakeholder map is diverse. Biopharma manufacturers are scaling R&D pipelines for oncology-focused biosimilars. Hospitals, specialty oncology clinics, and infusion centers are actively adopting them for treatment protocols. Governments and payers are setting tender-based procurement systems to boost competition. Investors, meanwhile, are treating biosimilars as a long-term growth story in biologics rather than a short-term generics play.

 

To be honest, bevacizumab biosimilars are no longer just an alternative—they’re becoming a strategic lever for expanding oncology care globally. The next six years will determine how quickly payers, providers, and patients transition from branded biologics to equally effective, more affordable biosimilars.

 

Market Segmentation And Forecast Scope

The bevacizumab biosimilars market is segmented across multiple dimensions to capture its therapeutic relevance, commercialization pathways, and regional dynamics. These segments highlight how developers, payers, and providers align around clinical demand and affordability goals.

By Indication

Bevacizumab biosimilars are used across several oncology indications, each reflecting the central role of VEGF inhibition in cancer therapy.

• Colorectal Cancer: Still the largest application, accounting for nearly one-third of global usage in 2024. Treatment guidelines increasingly recommend biosimilars to control costs without compromising outcomes.

• Lung Cancer: Rapidly expanding, especially in Asia-Pacific, where incidence rates and smoking-related cases remain high.

• Renal Cell Carcinoma: Gaining traction as biosimilars are incorporated into combination regimens with immunotherapies.

• Other Cancers: Includes ovarian, glioblastoma, and breast cancer (in certain markets), which together form a growing but fragmented demand base.

Colorectal cancer currently leads in share, but lung cancer is projected to be the fastest-growing indication segment through 2030.

 

By Distribution Channel

The distribution of bevacizumab biosimilars is primarily shaped by procurement and treatment settings.

• Hospital Pharmacies: Dominant channel in 2024, since bevacizumab requires infusion in controlled environments. Hospitals also benefit from bulk purchasing agreements and government tenders.

• Specialty Clinics: Increasingly important as oncology care shifts to outpatient centers , especially in developed economies.

• Online and Retail Pharmacies: Still limited but emerging in regions where home infusion models or direct-to-patient biologics delivery are being piloted.

Hospital pharmacies will remain the backbone of distribution, but specialty clinics are expected to gain market share steadily over the forecast period.

 

By End User

Adoption patterns differ based on the type of healthcare facility.

• Large Hospitals and Cancer Institutes: Early adopters due to direct involvement in clinical trials, established reimbursement pathways, and ability to negotiate biosimilar contracts.

• Community Oncology Centers : Growing segment where affordability pressures drive faster uptake compared to branded Avastin.

• Research Institutions: Smaller in scale but significant for real-world evidence generation and post-marketing surveillance of biosimilars.

 

By Region

The global footprint of bevacizumab biosimilars is uneven, shaped by regulatory maturity, cancer incidence, and healthcare financing models.

• North America: The U.S. market is scaling up, driven by payer pressure and increasing physician confidence in oncology biosimilars.

• Europe: Leads in adoption, with tender-driven pricing models and supportive biosimilar substitution policies. Germany, France, and the UK are front-runners.

• Asia Pacific: Fastest-growing region, led by China and India, where rising cancer incidence and government support for biosimilars are reshaping access.

• Latin America, Middle East & Africa: Still emerging, with uptake concentrated in Brazil, Mexico, Saudi Arabia, and South Africa through public health programs.

Scope Note: While these segments reflect therapeutic and commercial alignment, they also show where market battles will play out. Hospital tenders in Europe, insurance-driven substitution in the U.S., and government-backed procurement in Asia-Pacific will define the growth trajectory between 2024 and 2030.

 

Market Trends And Innovation Landscape

The bevacizumab biosimilars market is evolving beyond simple cost substitution. It’s becoming a testing ground for how biosimilars can reshape oncology care globally. Between 2024 and 2030, three forces—innovation, pricing strategy, and regulatory clarity—are converging to define how this market grows.

Shift from Cost Savings to Value-Based Integration

When bevacizumab biosimilars first entered the market, adoption was framed around price reduction versus branded Avastin. That’s changing. Now, hospitals and payers want more than discounts—they expect integrated value. Companies are bundling biosimilars with patient support programs, training modules for oncologists, and real-world evidence studies. This shift strengthens trust and accelerates prescribing behavior .

 

Expansion of Indication Approvals

One major trend is the broadening of approved indications. Initially launched for metastatic colorectal cancer, biosimilars are steadily gaining clearances for lung, renal, ovarian, and glioblastoma. This expansion mirrors the reference drug’s original label and increases addressable patient populations. It also lowers the barrier for oncologists to adopt biosimilars across multiple tumor types.

 

Manufacturing and Supply Chain Upgrades

Biologics manufacturing has always been complex. To compete, biosimilar developers are investing in next-generation production facilities, often in partnership with contract manufacturing organizations (CMOs). The emphasis is on consistency, global scale, and rapid response to demand spikes. Some players are even co-locating plants near major oncology hubs in Asia and Europe to ensure supply resilience.

 

Digital and AI-Enabled Pharmacovigilance

Safety and monitoring remain critical in biosimilar adoption. New pharmacovigilance platforms powered by AI are being deployed to track post-market outcomes. These tools can flag rare adverse events faster, giving regulators and providers confidence in long-term safety. Industry experts note that the ability to show real-world parity in safety and efficacy will likely be a stronger adoption driver than initial pricing alone.

 

Strategic Partnerships and Co-Marketing Deals

We’re also seeing a rise in partnerships between global biopharma companies and regional firms. Large multinationals often bring R&D and manufacturing expertise, while local partners provide distribution networks and access to reimbursement systems. For example, several alliances in Asia-Pacific are designed specifically to accelerate tender participation and expand physician outreach.

 

Patient and Physician Education Campaigns

A softer but important trend is the rise of education programs. Physician hesitancy remains a barrier in some markets, particularly in oncology where outcomes are critical. Biosimilar makers are funding training sessions, peer-reviewed comparative studies, and even patient advocacy campaigns to normalize biosimilar adoption. To be honest, trust is as important as clinical equivalence—and education is the bridge.

 

Emerging Innovations in Formulation

Some companies are exploring formulation changes to differentiate their biosimilars. While intravenous infusion remains standard, work is underway on subcutaneous delivery formats that could reduce infusion time and shift treatment closer to outpatient or home-care models. Though still in early development, such innovations could be game-changing for patient convenience and provider efficiency.

Bottom line: The innovation landscape here is not about reinventing bevacizumab—it’s about reinforcing confidence, expanding indications, and embedding biosimilars as a permanent fixture of oncology care.

 

Competitive Intelligence And Benchmarking

The bevacizumab biosimilars market is becoming increasingly competitive as multiple global and regional players vie for share in oncology’s most cost-sensitive space. Unlike small-molecule generics, biosimilar competition is defined not just by price, but by credibility, regulatory strategy, and long-term supply reliability. The companies succeeding are those that combine scientific rigor with smart commercialization.

Amgen

Amgen has established a strong foothold with its biosimilar portfolio in the U.S. and Europe. Its bevacizumab biosimilar strategy is anchored in early regulatory filings, robust real-world data generation, and payer engagement. Amgen leverages its existing oncology network to integrate biosimilars into treatment pathways while positioning itself as a trusted partner for large hospital systems.

 

Pfizer

Pfizer is building a diversified biosimilars pipeline, with bevacizumab being a key oncology pillar. The company’s edge lies in its expansive manufacturing footprint and long-standing relationships with oncology specialists. Pfizer has also invested in patient-support programs, focusing on education and adherence to address physician hesitancy in markets like the U.S.

 

Biocon Biologics

India-based Biocon Biologics, often in partnership with Mylan ( Viatris ), has emerged as a global force in biosimilars. The company’s bevacizumab biosimilar has achieved approvals in several regions, and it is aggressively targeting price-sensitive markets across Asia, Latin America, and Africa. Biocon’s strength lies in cost-efficient manufacturing and global alliances with payers and local distributors.

 

Roche (Indirect Role)

While Roche is the originator of Avastin, its influence in the biosimilars space remains indirect. The company continues to defend its branded revenues in some regions, but it is also repositioning its portfolio toward next-generation oncology drugs. Roche’s strong oncology presence means that biosimilar competitors must navigate entrenched provider relationships.

 

Samsung Bioepis

Samsung Bioepis , backed by Samsung Biologics, has made biosimilars a core growth driver. Its bevacizumab product is positioned with a dual focus: affordability for emerging markets and supply reliability for developed ones. Samsung’s integrated biologics manufacturing platform gives it scalability, which is particularly valuable for tender-driven European markets.

 

Celltrion

Celltrion has pursued aggressive expansion into oncology biosimilars, and bevacizumab plays a central role. The company is known for fast regulatory filings and competitive pricing, particularly in Europe and Asia. Beyond manufacturing, Celltrion differentiates itself through co-marketing partnerships with regional distributors, which boost penetration in underdeveloped markets.

 

Other Regional Players

Several regional manufacturers in China, Latin America, and the Middle East are developing locally produced bevacizumab biosimilars. While they may not compete head-to-head with multinational giants on quality or branding, they are winning public tenders due to lower pricing and government preference for domestic manufacturing.

 

Competitive Dynamics at a Glance

• Europe remains the most competitive landscape, with multiple biosimilars approved and battling for hospital tenders.

• North America is still consolidating, with only a few dominant players but growing payer-driven substitution.

• Asia-Pacific is becoming a hotbed of competition, as governments push local production alongside imports from multinationals.

• Trust, supply chain consistency, and supportive evidence generation are proving more decisive than headline discounts.

To be honest, this isn’t a crowded market in the traditional sense—it’s a high-stakes competition where a few global players set the pace, and regional challengers fill the affordability gaps. Success is less about being the cheapest and more about being the most reliable partner for oncology care.

 

Regional Landscape And Adoption Outlook

Adoption of bevacizumab biosimilars varies significantly across regions, shaped by regulation, healthcare financing, and oncology infrastructure. Some markets are accelerating biosimilar integration into cancer care, while others are just beginning to establish pathways.

North America

The U.S. market is expanding steadily but faces unique challenges. Physician hesitancy in oncology has historically slowed biosimilar uptake compared to small-molecule generics. However, payers are increasingly pushing biosimilar substitution as a way to reduce oncology drug costs. Medicare and commercial insurers are using formulary placement and step-therapy requirements to favor biosimilars. Large cancer institutes are now integrating biosimilars into protocols, especially for colorectal and lung cancer. Canada, with its centralized healthcare system, has adopted a more streamlined approach, with provincial programs mandating biosimilar switching.

 

Europe

Europe remains the leader in biosimilar adoption, supported by mature regulatory frameworks and price-competitive tender systems. Countries like Germany, the UK, and France have strong uptake driven by payer incentives and hospital purchasing agreements. Southern and Eastern European markets are also expanding access, though the pace depends on local tendering policies. Importantly, education campaigns led by medical societies in Europe have reduced physician resistance, allowing bevacizumab biosimilars to quickly gain traction in oncology centers .

 

Asia Pacific

This is the fastest-growing region for bevacizumab biosimilars. China and India dominate, given their large patient populations and increasing cancer incidence rates. China has actively supported domestic biosimilar development under its “Made in China” initiatives, while India’s cost-efficient production makes it a major supplier globally. Japan and South Korea, with advanced biologics regulation, are seeing strong uptake as well. Southeast Asian markets are also investing in biosimilars, often through public-private partnerships that expand access in middle-income countries.

 

Latin America

Adoption is uneven. Brazil and Mexico are leading the way, with regulatory approvals and public health systems integrating biosimilars to manage oncology costs. In other Latin American countries, limited oncology budgets and fragmented healthcare structures slow progress. However, regional alliances and international procurement programs are beginning to expand access.

 

Middle East and Africa

This region is still underpenetrated but gradually opening up. Wealthier Gulf states like Saudi Arabia and the UAE are adopting biosimilars through large hospital networks and government-led tenders. In Africa, affordability remains a barrier, though NGOs and donor-funded cancer programs are starting to introduce bevacizumab biosimilars in select hospitals. South Africa stands out as a regional hub for biosimilar adoption due to stronger regulatory capacity and oncology infrastructure.

 

Key Regional Dynamics

• North America is payer-driven, with insurers accelerating biosimilar adoption.

• Europe is regulation-driven, with tender-based competition setting the pace.

• Asia Pacific is volume-driven, with China and India shaping both supply and demand.

• Latin America and the Middle East are progressing through selective adoption, while Africa remains early-stage but strategically important for long-term growth.

The bottom line: regional adoption isn’t just about price. It’s about policy alignment, physician trust, and the ability to guarantee consistent supply. The fastest growth may come from Asia, but Europe remains the benchmark for biosimilar integration.

 

End-User Dynamics And Use Case

The adoption of bevacizumab biosimilars is shaped by the type of healthcare institution and how each balances cost containment with patient safety. End users here aren’t just buyers of a drug—they’re stakeholders who influence clinical acceptance, prescribing norms, and market momentum.

Large Hospitals and Cancer Institutes

These centers are the most significant adopters of bevacizumab biosimilars. They often participate in early-phase clinical studies or post-marketing research, which makes them more comfortable with substitution. Hospitals benefit from bulk procurement contracts and reimbursement alignment with payers, which often mandate biosimilar-first prescribing. Their size also allows them to manage pharmacovigilance protocols more effectively, reinforcing trust in switching from branded Avastin.

 

Community Oncology Clinics

Community-based oncology practices are increasingly important for scaling access. Here, the primary driver is cost-effectiveness. These clinics are highly responsive to payer-driven mandates, since reimbursement margins directly affect their operations. In regions like the U.S., where a large portion of cancer care is delivered outside major hospitals, community clinics are expected to be central to biosimilar penetration.

 

Specialty Pharmacies and Outpatient Infusion Centers

Outpatient infusion centers are becoming a growing channel as oncology care shifts away from inpatient settings. These centers adopt bevacizumab biosimilars primarily to provide lower-cost treatment options, appealing to both patients and insurers. Specialty pharmacies also play a role in facilitating supply, particularly in markets experimenting with direct-to-patient infusion models.

 

Research and Academic Institutions

Though not high-volume users, academic centers are influential in shaping perceptions. They conduct comparative studies, train the next generation of oncologists, and publish real-world evidence on biosimilar outcomes. Their role is less about consumption and more about credibility, which indirectly accelerates uptake across broader healthcare networks.

 

Use Case Highlight

A regional cancer network in Germany faced rising oncology drug costs, with bevacizumab accounting for a substantial share of chemotherapy expenditures. To reduce financial pressure, the network participated in a government-led hospital tender that awarded contracts to multiple biosimilar suppliers. Within one year of switching to biosimilars, the network achieved savings of over 20% on bevacizumab-related costs. These savings were reinvested in expanding immunotherapy access for lung cancer patients. Physicians initially expressed caution but quickly adapted after patient outcomes matched those seen with branded Avastin. Patient advocacy groups in the region later endorsed the transition, highlighting the role of biosimilars in democratizing cancer care.

This example underscores a critical point: biosimilar adoption isn’t just about price—it creates a ripple effect where cost savings can expand access to next-generation oncology treatments.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 Years)

• Amgen and Allergan received FDA approval for their bevacizumab biosimilar expansion into additional cancer indications, reinforcing confidence in regulatory acceptance.

• Biocon Biologics and Viatris announced successful commercialization of their bevacizumab biosimilar in multiple Asia-Pacific and Latin American markets, expanding global reach.

• Pfizer entered new supply agreements with U.S. hospital networks to integrate its bevacizumab biosimilar into standard oncology treatment protocols.

• Samsung Bioepis secured approvals in several European countries and expanded production capacity through new biologics facilities in South Korea.

• Celltrion partnered with regional distributors in the Middle East to boost access to oncology biosimilars, including bevacizumab, through government tenders.

 

Opportunities

• Expanding Indication Coverage: Broadening label approvals beyond colorectal cancer into lung, renal, and ovarian cancers will multiply addressable patient populations.

• Cost-Saving Potential: Biosimilars offer governments and payers a chance to reinvest oncology savings into next-generation therapies like immuno-oncology.

• Emerging Market Expansion: Asia-Pacific, Latin America, and parts of the Middle East are scaling biosimilar procurement, creating new revenue pools.

• Trust Through Real-World Evidence: Ongoing post-marketing data collection strengthens physician confidence and accelerates substitution.

 

Restraints

• Physician Hesitancy: Oncology specialists remain cautious in some markets, concerned about interchangeability and long-term outcomes.

• Pricing Pressure: Intense competition in Europe and Asia is driving prices down, potentially squeezing margins for manufacturers.

• Complex Manufacturing: Biosimilars require significant capital investment and rigorous compliance, limiting entry for smaller players.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 3.6 Billion
Revenue Forecast in 2030	USD 9.2 Billion
Overall Growth Rate	CAGR of 17.0% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Indication, Distribution Channel, End User, Geography
By Indication	Colorectal Cancer, Lung Cancer, Renal Cell Carcinoma, Others
By Distribution Channel	Hospital Pharmacies, Specialty Clinics, Online & Retail Pharmacies
By End User	Large Hospitals & Cancer Institutes, Community Oncology Clinics, Research & Academic Institutions
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, Germany, UK, France, China, India, Japan, Brazil, Saudi Arabia, South Africa, etc.
Market Drivers	- Rising global cancer incidence - Cost pressures on oncology budgets - Regulatory support for biosimilar adoption
Customization Option	Available upon request